Trial reportHaematologica2014
Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse.
Trial report in Haematologica, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
111 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Outcomes in patients with relapsed/refractory multiple myeloma with extramedullary disease: a meta-analysis.Annals of hematology · 2025Pooled it
- Extramedullary disease in multiple myeloma: a systematic literature review.Blood cancer journal · 2022Pooled it
- Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs.Haematologica · 2020Pooled it
- Efficacy and safety of selinexor combined with VRD in newly diagnosed multiple myeloma with EMD: a phase 2 trial.Blood advances · 2026Trial
- A randomized phase II, open-label and multicenter study of combination regimens of bortezomib at two doses by subcutaneous injection for newly diagnosed multiple myeloma patients.Journal of cancer research and clinical oncology · 2019Trial
- Prognosis of Extramedullary Disease in Chinese Newly Diagnosed Multiple Myeloma Patients Treated With Novel Agents-Based Induction Therapy.Cancer medicine · 2026Article
- Article
- High-risk genomic features predict extramedullary progression in multiple myeloma with paraskeletal plasmacytomas.HemaSphere · 2026Article
- Review
- Extramedullary Disease-Achilles Heel in Myeloma?American journal of hematology · 2026Review
- Unmasking multiple myeloma first presentation as pericardial effusion with tamponade physiology: a case report.Journal of medical case reports · 2026Article
- Daratumumab-based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study.HemaSphere · 2026Article
- Plasmacytomas in Extramedullary Manifestation of Multiple Myeloma: A Case Report.Clinical medicine insights. Case reports · 2026Article
- Multiple myeloma complicated with spinal infiltration: a case report.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- Review
- Patterns of relapse in patients with multiple myeloma receiving chimeric antigen receptor T cell therapy: a multi-center analysis.Leukemia · 2025Article
- Therapeutic options for extramedullary involvement in multiple myeloma.Clinical and experimental medicine · 2025Review
- Extramedullary disease but not paraskeletal disease portends inferior outcomes after CAR T cell therapy in multiple myeloma.Bone marrow transplantation · 2025Article
- Challenges, Difficulties, and Delayed Diagnosis of Multiple Myeloma.Diagnostics (Basel, Switzerland) · 2025Review
- Extramedullary disease in multiple myeloma at diagnosis and over the course of the disease.International journal of hematology · 2025Article
51 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Even in the era of new drugs, multiple myeloma patients with extramedullary relapse have a poor prognosis. Our goal was to analyze the frequency and outcome of extramedullary relapse occurring in relapsed multiple myeloma patients. In total, we analyzed the prognosis of 226 relapsed multiple myeloma patients treated between 2005 and 2008 and evaluated them for presence of extramedullary relapse. We found evidence of extramedullary relapse in 24% (55 of 226) of relapsed multiple myeloma patients. In 14% (32 of 226) of patients, the lesions were not adjacent to the bone, while extramedullary relapse adjacent to the bone was documented in 10% (23 of 226) of cases. Patients without extramedullary relapse had significantly longer overall survival than patients with extramedullary relapse (109 vs. 38 months; P<0.001). Moreover, patients with soft tissue-related extramedullary relapse had significantly poorer overall survival compared to bone-related extramedullary relapse patients (30 vs. 45 months; P=0.022). Also, overall survival from diagnosis was as low as five months for soft tissue-related extramedullary relapse patients when compared to 12 months overall survival for bone-related extramedullary relapse. This is the first study that shows a significant difference in prognosis for different types of extramedullary relapse. If the extramedullary myeloma infiltration was not bone-related, overall survival after relapse was extremely short (5 months).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.